Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice.

Cellular and Molecular Neurobiology
Chie OkiTsutomu Araki

Abstract

The authors investigated the protective effects of a novel astrocyte-modulating agent, arundic acid, in a 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine (MPTP) mouse model of Parkinson's disease. Male mice received four intraperitoneal (i.p.) injections of MPTP (20 mg/kg) at 2 h intervals. The content of dopamine and its metabolites in the striatum was reduced markedly 7 days after MPTP treatment. The delayed treatment with arundic acid (30 mg/kg, i.p.) administered 3, 4, 5 and 6 days after MPTP treatment did not affect the depletion of dopamine and its metabolites in the striatum. Our immunohistochemical study with anti-tyrosine hydroxylase antibody, anti-neuronal nuclei antibody, anti-glial fibrillary acidic protein antibody, anti-S 100beta antibody and anti-nestin antibody showed that the delayed treatment with arundic acid had a protective effect against MPTP-induced neuronal damage in the striatum and the substantia nigra of mice. Furthermore, this agent ameliorated the severe reductions in number of isolectin reactive microglia in the striatum and the substantia nigra 7 days after MPTP treatment. These results demonstrate that the inhibition of S 100beta synthesis in astrocytes may be the major component of the beneficial ef...Continue Reading

References

Jun 1, 1991·Lancet·Y Agid
Jan 7, 1998·Trends in Neurosciences·J L RidetF H Gage
Dec 13, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·T ArakiY Itoyama
Dec 18, 2001·Journal of Neuroscience Research·S G KernieL F Parada
Jun 5, 2002·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Toru MatsuiTakao Asano
Dec 25, 2002·Neurobiology of Aging·Rumiko KurosakiTsutomu Araki
May 26, 2004·Pharmacology, Biochemistry, and Behavior·Rumiko KurosakiTsutomu Araki
Mar 14, 2007·Mechanisms of Ageing and Development·Natsumi HayakawaTsutomu Araki

❮ Previous
Next ❯

Citations

Oct 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mary E Hamby, Michael V Sofroniew
Dec 17, 2009·Antioxidants & Redox Signaling·Amadou K S CamaraDavid F Stowe
Oct 13, 2010·Biochemical and Biophysical Research Communications·Marina YamadaMasao Kaneki
Jun 23, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Young C ChungByung K Jin
Jun 21, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sue H HuhByung K Jin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes in Repair & Regeneration

Astrocytes are glial cells found within the CNS and are able to regenerate new neurons. They become activated during CNS injury and disease. The activation leads to the transcription of new genes and the repair and regeneration of neurons. Discover the latest research on astrocytes in repair and regeneration here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.